|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Prostate Cancer | |||||
| Bladder Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplasm Metastasis | |||||
| Prostatic Neoplasms | |||||
| Urinary Bladder Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Genital Diseases, Male | |||||
| Genital Neoplasms, Male | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Neoplastic Processes | |||||
| Pathologic Processes | |||||
| Prostatic Diseases | |||||
| Urinary Bladder Diseases | |||||
| Urogenital Neoplasms | |||||
| Urologic Diseases | |||||
| Urologic Neoplasms | |||||
| 4 | Interventions listed in this trial | ||||
| Imaging: diffusion-weighted MRI | |||||
| Sinerem (USPIO) enhanced MRI | |||||
| 5 | Sponsors listed in this trial | ||||
| University Hospital Inselspital, Berne | |||||
| Swiss National Science Foundation | |||||